Clinical Trial Update: Trial of High-dose Urso in Primary Sclerosing Cholangitis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis was terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerosing Cholangitis

Drugs mentioned

• Ursodeoxycholic acid (ursodeoxycholic acid)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Primary Sclerosing Cholangitis | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2021-04-08